Why Venezuela is emerging as a top destination for first-in-human clinical trials

· bioaccess® Editorial Team

Venezuela offers treatment-naive populations, physician capacity confirmed per protocol, and lower costs for first-in-human trials — with an study-specific startup timeline.

Why Venezuela is a top first-in-human trial destination: treatment-naive populations, physician capacity confirmed per protocol, lower costs,.

Venezuela offers treatment-naïve populations, physician capacity confirmed per protocol, costs that are confirmed for the protocol, and enrollment that is confirmed for the protocol — making it a strategic destination for first-in-human trials.

June 5, 2026

15

min read

By

bioaccess® Editorial Team

first-in-human clinical trial Venezuela

Venezuela FIH destination

clinical trials Latin America

treatment-naive populations

FIH CRO Venezuela

**Key Takeaways**

  • • Treatment-naïve populations: Ideal for novel drug and device evaluation with clean baselines
  • • physician capacity confirmed per protocol: Large pool of GCP-trained investigators with international experience
  • • Costs confirmed per protocol: Lowest operational costs in Latin America
  • • Fast enrollment: High disease prevalence and eager patient populations
  • • bioaccess®: Founded in 2010. Leadership has more than two decades of experience with complex, advanced cardiovascular technologies and regulatory agencies from Mexico to Argentina

**The short answer**

Venezuela is emerging as a top first-in-human destination on four strengths: treatment-naïve populations that give clean baselines for novel drugs and devices, physician capacity confirmed per protocol with GCP training and international experience, Costs confirmed per protocol versus traditional markets, and enrollment that is confirmed for the protocol from high disease prevalence. The INHRR pathway delivers startup in a study-specific timeline, and bioaccess® — a first-in-human CRO founded in 2010 —. See how INHRR approval works for the regulatory detail.

Why is Venezuela emerging as an FIH destination?

In the global landscape of first-in-human clinical trials, Venezuela is emerging as one of the most compelling new destinations. While the country is less frequently discussed than established LATAM research markets like Mexico, Colombia, or Brazil, Venezuela offers a unique combination of strategic advantages that make it particularly attractive for FIH and early-phase studies.

bioaccess® is the a first-in-human CRO founded in 2010, bringing its specialized FIH expertise to this underserved but high-potential market.

Why do treatment-naïve populations matter for FIH trials?

One of Venezuela's most significant advantages for FIH trials is access to treatment-naïve patient populations. Due to limited access to newer therapies available in the US and Europe, many Venezuelan patients have not been exposed to standard-of-care treatments, creating exceptionally clean baselines for evaluating novel compounds and devices.

For first-in-human studies, treatment-naïve populations offer:

  • Cleaner pharmacokinetic and pharmacodynamic profiles without drug-drug interactions
  • More pronounced and measurable treatment effects
  • Reduced confounding from prior therapy exposure
  • Better signal detection for safety and efficacy endpoints
  • Higher enrollment rates due to unmet medical needs

How is investigator capacity confirmed for a Venezuela study?

Venezuela's medical education system has historically been one of the strongest in Latin America, producing investigator capacity that is confirmed for the protocol. Many Venezuelan doctors received training at internationally recognized institutions and maintain current GCP certifications.

The physician workforce includes specialists across virtually every therapeutic area, from cardiology and oncology to neurology and rare diseases. bioaccess® has identified and investigators confirmed for the proposed protocol across multiple specialties and cities, creating a ready-to-activate network for sponsors.

What drives study costs in Venezuela?

Operating costs in Venezuela are low in our experience, driven by site, investigator and monitoring costs.

For budgeting: budget depends on study design; we provide a study-specific quote.

Why do bilingual investigators and research staff matter?

A significant practical advantage of Venezuela for US-based sponsors is the prevalence of bilingual (Spanish-English) investigators and study staff. Many Venezuelan physicians completed fellowships or advanced training in the United States, making communication with sponsors seamless.

This bilingual capability streamlines:

  • Sponsor-investigator meetings and study training sessions
  • Protocol interpretation and implementation
  • Safety reporting and medical monitoring communications
  • FDA interaction preparation and data package development
  • Manuscript preparation and conference presentations

How fast can FIH sponsors enroll in Venezuela?

Venezuela's combination of high disease prevalence, treatment-naïve populations, and patient eagerness to access innovative therapies creates conditions for rapid clinical trial enrollment. In many therapeutic areas, enrollment in Venezuela can be faster than in the US.

**Enrollment acceleration**

For sponsors who have experienced slow enrollment in US sites, adding Venezuelan sites through bioaccess® can dramatically accelerate overall program timelines. Venezuela's large, underserved patient populations are highly motivated to participate in clinical trials, particularly for conditions where local treatment options are limited.

How does the INHRR regulatory framework work for FIH?

Venezuela's regulatory authority, INHRR (Instituto Nacional de Higiene Rafael Rangel), oversees clinical trial authorization. The INHRR follows international standards and the approval process varies by study (we confirm it per protocol). For detailed guidance on the INHRR approval process, see our complete regulatory guide.

Medical device registration through SACS offers an exceptionally fast study-specific timeline, making Venezuela attractive for market access alongside clinical research.

What experience does bioaccess® bring to a Venezuela assessment?

bioaccess® was founded in 2010. Leadership has more than two decades of experience with complex, advanced cardiovascular technologies and with regulatory agencies across Latin America, from Mexico to Argentina. A Venezuela study is scoped for the proposed protocol. Sites, investigators, recruitment and timelines are confirmed then. This page does not promise an approval date, a discount, or a site count.

  • Founded in 2010; leadership experience across Latin America
  • Pre-qualified investigator network across Caracas, Valencia, Maracaibo, and Barquisimeto
  • End-to-end regulatory support from INHRR submission to site activation
  • Scope, fees and timelines are confirmed in the written proposal
  • 50+ medtech companies supported across Latin America

What FIH success stories has bioaccess® delivered?

While bioaccess®'s Venezuelan operations are the newest addition to our LATAM network, our track record across the region demonstrates the model:

  • Supira Medical: FIH in Paraguay — 70+ patients, zero complications, now in US pivotal trial
  • Ocumetics Technology: FIH bioelectronic lens trial in Mexico — positive 3-month results
  • enVVeno Medical: bioaccess® supported early first-in-human clinical work in Colombia; enVVeno's non-surgical enVVe® System received the first-ever FDA IDE approval for a U.S. pivotal study (TAVVE®) on April 29, 2026 (IDE authorizes the STUDY, not device approval)
  • Unravel Biosciences: Proof-of-concept in Colombia — first RTT/PTHS trials in Latin America

**Ready to explore Venezuela for your FIH trial?**

bioaccess® is the FIH-focused CRO with operations in Venezuela. Contact us to discuss your clinical program, or take our Pre-FIH Assessment to evaluate your readiness.

Frequently asked questions

Planning your next step in Venezuela?

Explore clinical-trial planning for protocol-specific research questions, or medical-device registration and market access for SACS documentation and local registration arrangements. These are separate regulatory workstreams.

Launch your FIH trial in Venezuela with bioaccess®

The FIH-focused CRO, now operating in Venezuela — Latin America's most cost-effective clinical trial destination.

Get your FIH roadmap

View case studies

Frequently asked questions

Why is Venezuela a good destination for first-in-human clinical trials?

Venezuela offers several strategic advantages for FIH trials: treatment-naïve patient populations ideal for novel therapies, investigator capacity confirmed per protocol, costs confirmed for the protocol, enrollment that is confirmed for the protocol potential due to high disease prevalence, and a regulatory framework (INHRR) that follows international GCP standards.

What does 'treatment-naïve' mean and why does it matter for FIH trials?

Treatment-naïve patients have not been exposed to standard-of-care therapies available in developed markets. For FIH trials, this is advantageous because it provides a cleaner baseline for evaluating novel drugs or devices, reduces confounding variables from prior treatments, and can demonstrate more pronounced treatment effects.

How many physicians are available for clinical research in Venezuela?

Venezuela has investigator capacity that has to be confirmed for the protocol, many with international training and GCP certification. The country's medical education system has historically produced high-quality clinicians, and the private hospital infrastructure remains fully operational and well-equipped for clinical research.

What cost savings can sponsors expect in Venezuela?

Sponsors conducting clinical trials in Venezuela can expect lower costs compared to traditional markets like the US. These savings come from site and investigator fees, patient screening costs, and overall operational expenses, while maintaining ICH-GCP quality standards.

What experience does bioaccess® bring to a Venezuela assessment?

bioaccess® is a first-in-human CRO founded in 2010, bringing its specialized FIH expertise to a market that was previously underserved by international CROs. bioaccess® offers a complete operational infrastructure including regulatory submissions, site management, and clinical monitoring.

Topics

← Back to Blog · Contact bioaccess®